ss-31 peptide sequence Things to Know,31 peptide

The SS-31 peptide sequence has emerged as a significant area of research, particularly for its profound impact on mitochondrial function. Often referred to by its development codes such as Elamipretide and Bendavia, and also known as MTP-131, this synthetic tetrapeptide has demonstrated remarkable potential in therapeutic applications. Its unique ability to target and protect mitochondria, the powerhouses of our cells, positions it as a promising agent for addressing a range of health conditions.

At its core, the SS-31 peptide is characterized by its specific amino acid arrangement. The widely recognized sequence is D-Arg-dimethyl-Tyr-Lys-Phe-NH2, often abbreviated as D-Arg-Dmt-Lys-Phe-NH2. This precise molecular structure, with a molar weight of approximately 639.8 g/mol, is fundamental to its biological activity. Variations of this sequence, such as Arg-Tyr-Lys-Phe, have also been explored in research. The SS-31 peptide is a cell-permeable aromatic cationic tetrapeptide, a description that highlights its ability to traverse cell membranes and its inherent positive charge, which aids in its accumulation within the negatively charged environment of the mitochondria.

The primary mechanism of action for SS-31 revolves around its interaction with the inner mitochondrial membrane. Unlike many other peptides or antioxidants, SS-31 selectively accumulates within this critical cellular component. This targeted accumulation allows it to actively engage in supporting mitochondrial health. Research indicates that SS-31 acts as a mitochondrial targeted antioxidant peptide, playing a crucial role in scavenging reactive oxygen species and protecting mitochondrial components from damage. This protective function is vital, as mitochondrial dysfunction is implicated in numerous age-related diseases and physiological decline.

The therapeutic implications of SS-31 are broad and continue to be explored. Its ability to improve mitochondrial function has led to investigations into its efficacy in conditions such as heart failure, where mitochondrial defects are a significant contributor to disease progression. Furthermore, SS-31, a novel mitochondria-targeted peptide, has shown promise in neuroprotection, offering potential benefits for various neurological diseases. Studies have demonstrated its capacity to provide neuroprotection by reversing mitochondrial dysfunction. In some contexts, SS-31 (peptide) treatment has been shown to ameliorate cardiac mitochondrial morphology and defective mitophagy, particularly in models of conditions like Barth syndrome. In fact, Elamipretide (development codes SS-31, MTP-131) is a medication used for the treatment of Barth syndrome.

The Szeto-Schiller peptide (SS-31) has proven effective in counteracting mitochondrial dysfunction observed in aging and several diseases. Its capacity to easily penetrate cells and accumulate in mitochondria is key to its therapeutic potential. Researchers are actively investigating SS-31 peptide benefits, exploring its role in injury recovery and metabolic health. Some protocols suggest that ss31 repairs the mitochondrial membrane first, highlighting its direct impact on cellular integrity.

Beyond its direct impact on mitochondria, SS-31 is also being studied in conjunction with other compounds and peptides. Discussions around how to properly utilize and stack SS-31 with other agents like MOTS-C and NAD+ are emerging in the performance enhancement and longevity communities. While MOTS-c is noted for improving insulin sensitivity and building new mitochondria, SS-31 focuses on repairing existing mitochondrial membranes.

For those interested in practical application, information regarding how to properly reconstitute your SS-31 peptide is essential for maintaining its integrity and efficacy. Proper reconstitution is a critical step in its preparation for use. Understanding SS-31 peptide dosage and SS-31 peptide protocol is a common area of inquiry, with various SS-31 peptide dosage charts and SS-31 peptide dosage protocols being discussed in research and user forums, though specific medical advice should always be sought from qualified professionals. The SS-31 peptide is a subject of ongoing scientific inquiry, with its sequence and mechanisms of action being central to unlocking its full therapeutic potential.